Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
BAVENCIO (Merck Serono Australia Pty Ltd)
Product name
BAVENCIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
avelumab (rch)
Registration type
NCE/NBE
Indication
BAVENCIO is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel Cell Carcinoma (mMCC).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.